Efficacy of tricyclic antidepressants in irritable bowel syndrome: A meta-analysis

World Journal of Gastroenterology

Volumn 15, Issue 13, 2009, Pages 1548-1553

  Rahimi, Roja ^a   Nikfar, Shekoufeh ^b   Rezale, Ali ^c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Abdominal pain; Clinical response; Efficacy; Irritable bowel syndrome; Meta analysis; Systematic review; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; DESIPRAMINE; DOXEPIN; IMIPRAMINE; LAXATIVE; PLACEBO; PROBIOTIC AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DISEASE CONTROL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; EFFECT SIZE; ENVIRONMENTAL FACTOR; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; ARTICLE; DOUBLE BLIND PROCEDURE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOUBLE-BLIND METHOD; HUMANS; IRRITABLE BOWEL SYNDROME; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 64549119680     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1548     Document Type: Editorial

References (42)

1. Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am 2007; 36: 665-685, x
2. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S1-S5
3. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004; 54: 495-502
4. Croghan A, Heitkemper MM. Recognizing and managing patients with irritable bowel syndrome. J Am Acad Nurse Pract 2005; 17: 51-59
5. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-607
6. Bommelaer G, Dorval E, Denis P, Czernichow P, Frexinos J, Pelc A, Slama A, El Hasnaoui A. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol Clin Biol 2002; 26: 1118-1123
7. Foxx-Orenstein A. IBS - review and what's new. MedGenMed 2006; 8: 20
8. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; CD003460
9. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials. Arch Med Sci 2008; 4: 71-76
10. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30: 884-901
11. Fumi AL, Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008; 42: 408-412
12. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a metaanalysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-1780
13. Jadad A. Randomised controlled trials: a user's duide. London: BMJ Books, 1998
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
15. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
16. Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, Malekzadeh R. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 678-684
17. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008; 53: 108-115
18. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-607
19. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738-741
20. Vij JG, Jiloha RG, Kumar N, Madhu SV, Malika V, Anand BS. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry 1991; 33: 243-246
21. Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, Matson RW, Stein GE, Dean HA, Halvorsen NA. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32: 257-266
22. Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (trimipramine) vis-a-vis placebo in irritable bowel syndrome. (Double blind randomised study). J Assoc Physicians India 1983; 31: 201-203
23. Truong TT, Naliboff BD, Chang L. Novel techniques to study visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep 2008; 10: 369-378
24. Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006; 24: 919-933
25. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275: G460-G466
26. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48: 980-990
27. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72
28. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1253-1269
29. Myren J, Løvland B, Larssen SE, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19: 835-843
30. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31
31. Forootan H, Taheri A, Hooshangi H, Mohammadi HR. Effects of Fluoxetine, Nortriptyline and Amitriptyline in IBS patients. Feyz Kashan Univ Med Sci Health Serv 2002; 21: 49-55
32. Siproudhis L, Dinasquet M, Sébille V, Reymann JM, Bellissant E. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception. Aliment Pharmacol Ther 2004; 20: 689-695
33. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893
34. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4: 185-190
35. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-2531
36. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007; 13: PI13-PI18
37. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52: 2920-2925
38. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007; 61: 75-80
39. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983-1988
40. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 118-127
41. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008; 53: 1278-1284
42. Derakhshani S, Pakzad M, Vafaie M, Tehrani-Tarighat S, Abdollahi M. A report of 112 cases of solitary rectal ulcer syndrome from Iran. Cent Eur J Med 2009; 4: 49-53